These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 26391871)

  • 61. Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity.
    Derouazi M; Di Berardino-Besson W; Belnoue E; Hoepner S; Walther R; Benkhoucha M; Teta P; Dufour Y; Yacoub Maroun C; Salazar AM; Martinvalet D; Dietrich PY; Walker PR
    Cancer Res; 2015 Aug; 75(15):3020-31. PubMed ID: 26116496
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.
    Cecil DL; Holt GE; Park KH; Gad E; Rastetter L; Childs J; Higgins D; Disis ML
    Cancer Res; 2014 May; 74(10):2710-8. PubMed ID: 24778415
    [TBL] [Abstract][Full Text] [Related]  

  • 65. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells.
    Assudani D; Cho HI; DeVito N; Bradley N; Celis E
    Cancer Res; 2008 Dec; 68(23):9892-9. PubMed ID: 19047170
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign antigen.
    Sabarth N; Chamberlain L; Brett S; Tite J; Craigen J
    J Immunol; 2010 Oct; 185(8):4590-601. PubMed ID: 20861346
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
    Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunotherapy with tumor cell lysate-pulsed CD8α+ dendritic cells modulates intra-tumor and spleen lymphocyte subpopulations.
    Azadmehr A; Pourfathollah AA; Amirghofran Z; Hassan ZM; Moazzeni SM
    Neoplasma; 2013; 60(5):525-32. PubMed ID: 23790171
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
    Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
    Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes.
    Blohm U; Roth E; Brommer K; Dumrese T; Rosenthal FM; Pircher H
    J Immunol; 2002 Nov; 169(10):5522-30. PubMed ID: 12421928
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
    Yu Z; Tan Z; Lee BK; Tang J; Wu X; Cheung KW; Lo NT; Man K; Liu L; Chen Z
    Oncotarget; 2015 Oct; 6(32):32426-38. PubMed ID: 26431275
    [TBL] [Abstract][Full Text] [Related]  

  • 75. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
    Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
    J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator.
    Chang MC; Chen YL; Chiang YC; Chen TC; Tang YC; Chen CA; Sun WZ; Cheng WF
    Gene Ther; 2016 Jan; 23(1):38-49. PubMed ID: 26262583
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evaluation of anti-tumor effects of tumor cell lysate enriched by HSP-70 against fibrosarcoma tumor in BALB/c mice.
    Hashemi SM; Hassan ZM; Soudi S; Ghazanfari T; Kheirandish M; Shahabi S
    Int Immunopharmacol; 2007 Jul; 7(7):920-7. PubMed ID: 17499194
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice.
    Kasamatsu J; Takahashi S; Azuma M; Matsumoto M; Morii-Sakai A; Imamura M; Teshima T; Takahashi A; Hirohashi Y; Torigoe T; Sato N; Seya T
    Immunobiology; 2015 Jan; 220(1):74-82. PubMed ID: 25257859
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
    Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
    Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.